Penn researchers at Penn Dental Medicine, Penn Medicine and Penn Engineering led by Michel Koo, DDS, MS, PhD, Professor, Department of Orthodontics at Penn Dental, identified ferumoxytol, an FDA-approved iron oxide nanoparticle, as a highly effective alternative to traditional root canal disinfectants, reducing bacterial infections by 99.9% without harmful side effects.
Unlike conventional treatments, ferumoxytol nanozymes not only eliminate biofilm infections but also stimulate stem cells to promote bone regeneration, potentially revolutionizing tissue healing in dental care. Beyond root canals, nanozymes could also be applied to treat craniofacial bone defects, osteoporosis, and periodontitis, offering a cost-effective and regenerative approach to antimicrobial therapy.
PCI is actively seeking partners and investors for further development of this exciting technology. For more information, please contact Neetu Amin, PhD, Assistant Director, Licensing at PCI. Read more about the technology here.